What's new

Orphan designation: autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 Treatment of myasthenia gravis, 20/02/2025 Positive

Orphan designation: autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 Treatment of myasthenia gravis, 20/02/2025 Positive

Mar 12, 2025 - 17:06
 0
Orphan designation: autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 Treatment of myasthenia gravis, 20/02/2025 Positive
Orphan designation: autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 Treatment of myasthenia gravis, 20/02/2025 Positive
Read More

Tags:

Previous Article

Who’s Who in Defense: Jack Reed, Ranking Member, Senate Armed Services Committee...

Next Article

Orphan designation: Magrolimab Treatment of acute myeloid leukaemia, 11/11/2015 ...

Related Posts

EMA Open Door Day, European Medicines Agency, Amsterdam, the Netherlands, from 9 May 2025, 09:45 (CEST) to 9 May 2025, 16:00 (CEST)

EMA Open Door Day, European Medicines Agency, Amsterdam...

Feb 18, 2025  0

Human medicines European public assessment report (EPAR): Vueway, Gadopiclenol, Date of authorisation: 07/12/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Enyglid, repaglinide, Date of authorisation: 13/10/2009, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0